Cite
HARVARD Citation
Amin, A. et al. (2017). Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population. Current medical research and opinion. pp. 1595-1604. [Online].